Our data suggest that in order to reduce the risk of non-AIDS events in people starting therapy with a CD4<350 cells/μl, continuous monitoring for difference between current CD4 count and the level registered at the time of initiation of a new regimen may be considered starting as early as the first 6 months following viral suppression. This evidence concerns the gene CD4 and AIDS.